Topical peptide eye drop promising for wet age-related macular degeneration

NEW ORLEANS — In this video, David Almeida, MD, MBA, PhD, discusses the safety, tolerability and pharmacodynamic signal of CG-P5, a topical peptide eye drop, in patients with wet age-related macular degeneration.
Almeida, of Erie Retina Research in Pennsylvania, said that up to 40% of patients being treated for wet AMD do not meet treatment expectations.
In a phase 1 study presented at the American Academy of Ophthalmology meeting, patients with treatment-experienced wet AMD were randomly assigned to receive CG-P5 (Caregen), Eylea (aflibercept 2 mg, Regeneron) or placebo for 84 days.

OCU410 gene therapy shows potential in geographic atrophy

NEW ORLEANS — In this video, Jennifer I. Lim, MD, discusses phase 2 data on OCU410 presented at the American Academy of Ophthalmology meeting.
The trial evaluated OCU410 (Ocugen) subretinal gene therapy in patients with geographic atrophy. The one-time injection reduced the rate of ellipsoid zone loss by 27% and the rate of retinal pigment epithelium loss by 45%.
Lim called OCU410 a “promising potential new treatment” and noted that the phase 3 ArMaDa study of the therapy is ongoing.
Reference:

Early use of GA drugs provides longer protection of vision

NEW ORLEANS — In this video from the American Academy of Ophthalmology meeting, Sunir J. Garg, MD, FACS, FASRS, discusses what has been learned from phase 3 data on two FDA-approved treatments for geographic atrophy.
Garg, of Wills Eye Hospital, noted that with pegcetacoplan, patients with nonsubfoveal geographic atrophy responded to treatment better that patients with subfoveal lesions. In addition, over time, both Syfovre (pegcetacoplan injection, Biogen) and Izervay (avacincaptad pegol intravitreal solution, Astellas) showed additive benefit of treatment at 12 months, 18 months and 24